Research programme: eye disorders cell therapy - CelogosAlternative Names: RCD-3
Latest Information Update: 24 Jul 2006
At a glance
- Originator Celogos
- Class Cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Blepharoptosis; Eye disorders
Most Recent Events
- 24 Jul 2006 Preclinical trials in Eye disorders in France (Ophthalmic)
- 24 Jul 2006 Preclinical trials in Blepharoptosis in France (Ophthalmic)